APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Melatonin Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting Melatonin Receptor Agonists Market Outlook and Growth Opportunities 2026

20 December 2025192 pages

Choose your research edition.

Industry ResearchLong-acting Melatonin Receptor Agonists Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Melatonin Receptor Agonists Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Long-acting Melatonin Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Melatonin Receptor Agonists Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Melatonin Receptor Agonists Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Long-acting Melatonin Receptor Agonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting Melatonin Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Melatonin Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Melatonin Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting Melatonin Receptor Agonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting Melatonin Receptor Agonists market include Takeda, Sichuan Kelun Pharmaceuticals, Sichuan Guowei Pharmaceuticals, Novartis, Jiangsu Hausen Pharmaceuticals, Hangzhou Lingye Pharmaceutical Technology, Guangdong Annuo Pharmaceuticals, Vanda Pharmaceuticals and Servier Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Long-acting Melatonin Receptor Agonists market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Melatonin Receptor Agonists and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Melatonin Receptor Agonists revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Long-acting Melatonin Receptor Agonists market.

Long-acting Melatonin Receptor Agonists Segment by Company

Takeda

Sichuan Kelun Pharmaceuticals

Sichuan Guowei Pharmaceuticals

Novartis

Jiangsu Hausen Pharmaceuticals

Hangzhou Lingye Pharmaceutical Technology

Guangdong Annuo Pharmaceuticals

Vanda Pharmaceuticals

Servier Laboratories

Rovi Pharma

Nectid Inc

Dr Reddy's Laboratories

Long-acting Melatonin Receptor Agonists Segment by Type

Ramelteon

Agomelatine

Other

Long-acting Melatonin Receptor Agonists Segment by Application

Hospital

Clinic

Other

Long-acting Melatonin Receptor Agonists Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Long-acting Melatonin Receptor Agonists status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Long-acting Melatonin Receptor Agonists key companies, revenue, market share, and recent developments.

3. To split the Long-acting Melatonin Receptor Agonists breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Long-acting Melatonin Receptor Agonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting Melatonin Receptor Agonists significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting Melatonin Receptor Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Melatonin Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Melatonin Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Melatonin Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Melatonin Receptor Agonists industry.

Chapter 3: Detailed analysis of Long-acting Melatonin Receptor Agonists company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Long-acting Melatonin Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Long-acting Melatonin Receptor Agonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting Melatonin Receptor Agonists Industry Trends Table 2. Long-acting Melatonin Receptor Agonists Industry Drivers Table 3. Long-acting Melatonin Receptor Agonists Industry Opportunities and Challenges Table 4. Long-acting Melatonin Receptor Agonists Industry Restraints Table 5. Global Long-acting Melatonin Receptor Agonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting Melatonin Receptor Agonists Revenue Share by Company (2021-2026) Table 7. Global Long-acting Melatonin Receptor Agonists Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Long-acting Melatonin Receptor Agonists Key Company Manufacturing Base & Headquarters Table 9. Global Long-acting Melatonin Receptor Agonists Company, Product Type & Application Table 10. Global Long-acting Melatonin Receptor Agonists Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Long-acting Melatonin Receptor Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ramelteon Table 15. Significant Companies of Agomelatine Table 16. Significant Companies of Other Table 17. Global Long-acting Melatonin Receptor Agonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Long-acting Melatonin Receptor Agonists Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Long-acting Melatonin Receptor Agonists Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Type (2021-2026) Table 21. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinic Table 24. Significant Companies of Other Table 25. Global Long-acting Melatonin Receptor Agonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Long-acting Melatonin Receptor Agonists Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Long-acting Melatonin Receptor Agonists Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Application (2021-2026) Table 29. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Application (2027-2032) Table 30. Global Long-acting Melatonin Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Long-acting Melatonin Receptor Agonists Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Region (2021-2026) Table 33. Global Long-acting Melatonin Receptor Agonists Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Region (2027-2032) Table 35. Global Long-acting Melatonin Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Long-acting Melatonin Receptor Agonists Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Long-acting Melatonin Receptor Agonists Sales Value Market Share by Country (2021-2026) Table 38. Global Long-acting Melatonin Receptor Agonists Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Long-acting Melatonin Receptor Agonists Sales Value Market Share by Country (2027-2032) Table 40. Takeda Company Information Table 41. Takeda Business Overview Table 42. Takeda Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Takeda Long-acting Melatonin Receptor Agonists Product Portfolio Table 44. Takeda Recent Development Table 45. Sichuan Kelun Pharmaceuticals Company Information Table 46. Sichuan Kelun Pharmaceuticals Business Overview Table 47. Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 49. Sichuan Kelun Pharmaceuticals Recent Development Table 50. Sichuan Guowei Pharmaceuticals Company Information Table 51. Sichuan Guowei Pharmaceuticals Business Overview Table 52. Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 54. Sichuan Guowei Pharmaceuticals Recent Development Table 55. Novartis Company Information Table 56. Novartis Business Overview Table 57. Novartis Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Novartis Long-acting Melatonin Receptor Agonists Product Portfolio Table 59. Novartis Recent Development Table 60. Jiangsu Hausen Pharmaceuticals Company Information Table 61. Jiangsu Hausen Pharmaceuticals Business Overview Table 62. Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 64. Jiangsu Hausen Pharmaceuticals Recent Development Table 65. Hangzhou Lingye Pharmaceutical Technology Company Information Table 66. Hangzhou Lingye Pharmaceutical Technology Business Overview Table 67. Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Product Portfolio Table 69. Hangzhou Lingye Pharmaceutical Technology Recent Development Table 70. Guangdong Annuo Pharmaceuticals Company Information Table 71. Guangdong Annuo Pharmaceuticals Business Overview Table 72. Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 74. Guangdong Annuo Pharmaceuticals Recent Development Table 75. Vanda Pharmaceuticals Company Information Table 76. Vanda Pharmaceuticals Business Overview Table 77. Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio Table 79. Vanda Pharmaceuticals Recent Development Table 80. Servier Laboratories Company Information Table 81. Servier Laboratories Business Overview Table 82. Servier Laboratories Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Servier Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio Table 84. Servier Laboratories Recent Development Table 85. Rovi Pharma Company Information Table 86. Rovi Pharma Business Overview Table 87. Rovi Pharma Long-acting Melatonin Receptor Agonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Rovi Pharma Long-acting Melatonin Receptor Agonists Product Portfolio Table 89. Rovi Pharma Recent Development Table 90. Nectid Inc Company Information Table 91. Nectid Inc Business Overview Table 92. Nectid Inc Long-acting Melatonin Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Nectid Inc Long-acting Melatonin Receptor Agonists Product Portfolio Table 94. Nectid Inc Recent Development Table 95. Dr Reddy's Laboratories Company Information Table 96. Dr Reddy's Laboratories Business Overview Table 97. Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio Table 99. Dr Reddy's Laboratories Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Long-acting Melatonin Receptor Agonists Product Image Figure 2. Global Long-acting Melatonin Receptor Agonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Melatonin Receptor Agonists Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Melatonin Receptor Agonists Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ramelteon Image Figure 8. Agomelatine Image Figure 9. Other Image Figure 10. Global Long-acting Melatonin Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Long-acting Melatonin Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Other Image Figure 16. Global Long-acting Melatonin Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Long-acting Melatonin Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Application (2021-2032) Figure 19. Global Long-acting Melatonin Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Long-acting Melatonin Receptor Agonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Long-acting Melatonin Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 22. North America Long-acting Melatonin Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Long-acting Melatonin Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Long-acting Melatonin Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Long-acting Melatonin Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Long-acting Melatonin Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Long-acting Melatonin Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 28. South America Long-acting Melatonin Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Long-acting Melatonin Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Long-acting Melatonin Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Ramelteon
  • Agomelatine
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Takeda
  • Sichuan Kelun Pharmaceuticals
  • Sichuan Guowei Pharmaceuticals
  • Novartis
  • Jiangsu Hausen Pharmaceuticals
  • Hangzhou Lingye Pharmaceutical Technology
  • Guangdong Annuo Pharmaceuticals
  • Vanda Pharmaceuticals
  • Servier Laboratories
  • Rovi Pharma
  • Nectid Inc
  • Dr Reddy's Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting Melatonin Receptor Agonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting Melatonin Receptor Agonists Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Long-acting Melatonin Receptor Agonists Market Dynamics
  1. 2.1 Long-acting Melatonin Receptor Agonists Industry Trends
  2. 2.2 Long-acting Melatonin Receptor Agonists Industry Drivers
  3. 2.3 Long-acting Melatonin Receptor Agonists Industry Opportunities and Challenges
  4. 2.4 Long-acting Melatonin Receptor Agonists Industry Restraints
3 Long-acting Melatonin Receptor Agonists Market by Company
  1. 3.1 Global Long-acting Melatonin Receptor Agonists Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting Melatonin Receptor Agonists Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting Melatonin Receptor Agonists Company Ranking (2024-2026)
  4. 3.4 Global Long-acting Melatonin Receptor Agonists Company Manufacturing Base and Headquarters
  5. 3.5 Global Long-acting Melatonin Receptor Agonists Company Product Type and Application
  6. 3.6 Global Long-acting Melatonin Receptor Agonists Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Long-acting Melatonin Receptor Agonists Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Long-acting Melatonin Receptor Agonists Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Long-acting Melatonin Receptor Agonists Market by Type
  1. 4.1 Long-acting Melatonin Receptor Agonists Type Introduction
  2. 4.1.1 Ramelteon
  3. 4.1.2 Agomelatine
  4. 4.1.3 Other
  5. 4.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Type
  6. 4.2.1 Global Long-acting Melatonin Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Type (2021-2032)
  8. 4.2.3 Global Long-acting Melatonin Receptor Agonists Sales Value Share by Type (2021-2032)
5 Long-acting Melatonin Receptor Agonists Market by Application
  1. 5.1 Long-acting Melatonin Receptor Agonists Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Application
  6. 5.2.1 Global Long-acting Melatonin Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Application (2021-2032)
  8. 5.2.3 Global Long-acting Melatonin Receptor Agonists Sales Value Share by Application (2021-2032)
6 Long-acting Melatonin Receptor Agonists Regional Value Analysis
  1. 6.1 Global Long-acting Melatonin Receptor Agonists Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Region (2021-2032)
  3. 6.2.1 Global Long-acting Melatonin Receptor Agonists Sales Value by Region: 2021-2026
  4. 6.2.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting Melatonin Receptor Agonists Sales Value (2021-2032)
  7. 6.3.2 North America Long-acting Melatonin Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Long-acting Melatonin Receptor Agonists Sales Value (2021-2032)
  10. 6.4.2 Europe Long-acting Melatonin Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Long-acting Melatonin Receptor Agonists Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Long-acting Melatonin Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Long-acting Melatonin Receptor Agonists Sales Value (2021-2032)
  16. 6.6.2 South America Long-acting Melatonin Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Long-acting Melatonin Receptor Agonists Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Long-acting Melatonin Receptor Agonists Sales Value Share by Country, 2025 VS 2032
7 Long-acting Melatonin Receptor Agonists Country-level Value Analysis
  1. 7.1 Global Long-acting Melatonin Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Country (2021-2032)
  3. 7.2.1 Global Long-acting Melatonin Receptor Agonists Sales Value by Country (2021-2026)
  4. 7.2.2 Global Long-acting Melatonin Receptor Agonists Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Long-acting Melatonin Receptor Agonists Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Long-acting Melatonin Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Long-acting Melatonin Receptor Agonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Long-acting Melatonin Receptor Agonists Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sichuan Kelun Pharmaceuticals
  8. 8.2.1 Sichuan Kelun Pharmaceuticals Company Information
  9. 8.2.2 Sichuan Kelun Pharmaceuticals Business Overview
  10. 8.2.3 Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Kelun Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  12. 8.2.5 Sichuan Kelun Pharmaceuticals Recent Developments
  13. 8.3 Sichuan Guowei Pharmaceuticals
  14. 8.3.1 Sichuan Guowei Pharmaceuticals Company Information
  15. 8.3.2 Sichuan Guowei Pharmaceuticals Business Overview
  16. 8.3.3 Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Guowei Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  18. 8.3.5 Sichuan Guowei Pharmaceuticals Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Long-acting Melatonin Receptor Agonists Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Jiangsu Hausen Pharmaceuticals
  26. 8.5.1 Jiangsu Hausen Pharmaceuticals Company Information
  27. 8.5.2 Jiangsu Hausen Pharmaceuticals Business Overview
  28. 8.5.3 Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Hausen Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  30. 8.5.5 Jiangsu Hausen Pharmaceuticals Recent Developments
  31. 8.6 Hangzhou Lingye Pharmaceutical Technology
  32. 8.6.1 Hangzhou Lingye Pharmaceutical Technology Company Information
  33. 8.6.2 Hangzhou Lingye Pharmaceutical Technology Business Overview
  34. 8.6.3 Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hangzhou Lingye Pharmaceutical Technology Long-acting Melatonin Receptor Agonists Product Portfolio
  36. 8.6.5 Hangzhou Lingye Pharmaceutical Technology Recent Developments
  37. 8.7 Guangdong Annuo Pharmaceuticals
  38. 8.7.1 Guangdong Annuo Pharmaceuticals Company Information
  39. 8.7.2 Guangdong Annuo Pharmaceuticals Business Overview
  40. 8.7.3 Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Guangdong Annuo Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  42. 8.7.5 Guangdong Annuo Pharmaceuticals Recent Developments
  43. 8.8 Vanda Pharmaceuticals
  44. 8.8.1 Vanda Pharmaceuticals Company Information
  45. 8.8.2 Vanda Pharmaceuticals Business Overview
  46. 8.8.3 Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Vanda Pharmaceuticals Long-acting Melatonin Receptor Agonists Product Portfolio
  48. 8.8.5 Vanda Pharmaceuticals Recent Developments
  49. 8.9 Servier Laboratories
  50. 8.9.1 Servier Laboratories Company Information
  51. 8.9.2 Servier Laboratories Business Overview
  52. 8.9.3 Servier Laboratories Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Servier Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio
  54. 8.9.5 Servier Laboratories Recent Developments
  55. 8.10 Rovi Pharma
  56. 8.10.1 Rovi Pharma Company Information
  57. 8.10.2 Rovi Pharma Business Overview
  58. 8.10.3 Rovi Pharma Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Rovi Pharma Long-acting Melatonin Receptor Agonists Product Portfolio
  60. 8.10.5 Rovi Pharma Recent Developments
  61. 8.11 Nectid Inc
  62. 8.11.1 Nectid Inc Company Information
  63. 8.11.2 Nectid Inc Business Overview
  64. 8.11.3 Nectid Inc Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nectid Inc Long-acting Melatonin Receptor Agonists Product Portfolio
  66. 8.11.5 Nectid Inc Recent Developments
  67. 8.12 Dr Reddy's Laboratories
  68. 8.12.1 Dr Reddy's Laboratories Company Information
  69. 8.12.2 Dr Reddy's Laboratories Business Overview
  70. 8.12.3 Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dr Reddy's Laboratories Long-acting Melatonin Receptor Agonists Product Portfolio
  72. 8.12.5 Dr Reddy's Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst